About us
Shanghai Best-Link Bioscience
Shanghai Best-Link Bioscience LLC was founded in 2021 and is a high-tech enterprise engaged in innovative drug research and development. Best-Link focuses on the development of novel nano-conjugate drugs and precise nano-drug delivery platforms based on advanced conjugation technology and nanotechnology to develop innovative drugs for precision cancer treatment and tumor immunotherapy. Best-Link adheres to the concept of "Benefiting the people and leading the future", and is committed to developing innovative drugs with better therapeutic effects, less toxic side effects, and better compliance.
Founded in 2021
200台
出口销售数量
2,000 square meters of office space
Benefiting the People and Leading the Future
Best-Link first proposed the concept of "Nano-Train Conjugate Drugs", which can effectively deliver conjugate drugs into the tumor microenvironment and selectively release their active payloads at a fixed time and location by controlling the delivery process. The active payloads released from the tumor microenvironment can penetrate effectively and deeply into the tumor, causing sustained damage to the tumor. Based on this concept, Best-Link has developed a novel nano-conjugate drug platform (NMPDC®) by integrating conjugation technology and nanotechnology. By effectively controlling the nano-conjugate’s particle size, charge, and release time and position, it has been addressed two key issues of ADC drugs: low delivery efficiency and low permeability.
Management Team